Evidence map›Paper›PMID 41310024›Full record

ReviewNature reviews. Neurology2026

Towards primary prevention of multiple sclerosis.

Ruth Dobson, Karim L Kreft, Benjamin M Jacobs, J William L Brown, Alison Thomson, Richard Nicholas, Clare Walton, Parth Narendran, UK MS Prevention Taskforce

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ruth DobsonCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University London, London, UK. Ruth.dobson@qmul.ac.uk.ORCID 0000-0002-2993-585X
Karim L KreftDepartment of Mental Health and Clinical Neuroscience, University of Nottingham, Nottingham, UK.ORCID 0000-0002-2966-5335
Benjamin M JacobsCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University London, London, UK.
J William L BrownDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.ORCID 0000-0002-7737-5834
Alison ThomsonCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University London, London, UK.ORCID 0000-0002-9299-0130
Richard NicholasDepartment of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
Clare WaltonMultiple Sclerosis Society, London, UK.ORCID 0000-0002-8128-6439
Parth NarendranDepartment of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
UK MS Prevention Taskforce

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is among the most common causes of disability in the young and, despite the advent of highly effective disease-modifying therapies, remains an incurable disease. Prevention of MS before the onset of demyelination is a feasible, albeit ambitious, goal. Currently, preventive interventions with adequate evidence of efficacy are lacking, and evaluating such interventions with traditional trial designs is challenging. Additionally, the high frequency and low effect sizes of putative MS risk factors, a limited window of opportunity to intervene, and the relatively low incidence of MS in the general population make prevention studies conceptually and practically difficult. Nevertheless, studies in radiologically isolated syndrome have generated momentum within the MS prevention space, and novel trial designs offer the potential for reimagining traditional randomized controlled trials. In this Perspective, we discuss the challenges in developing and testing preventive interventions in MS and, drawing on progress in other diseases, we propose strategies and solutions. We discuss pragmatic approaches to risk stratification and illustrate the importance of considering statistical power and outcome definitions. Prevention studies require careful thought with respect to risk stratification, communication, intervention and outcomes but, given the current knowledge, the time to set up and start MS prediction and prevention studies is now.

Indexed as

Multiple SclerosisPrimary PreventionHumans

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.